TAG delivered an intervention at the UN High-Level Meeting on Antimicrobial Resistance (AMR) Multistakeholder Hearing, calling on member states to incorporate drug-resistant TB (DR-TB) in the political declaration as a key component of AMR response.
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
TAG hosted this May 31 webinar on the growing pipeline of microarray patches (MAPs) for various infectious diseases treatment and immunization.
Follow along with one of our staff members on a typical day, and you'll see the difference you make as a TAG donor and partner.
1997 Michael Palm* Dr. David Ho 1998 Wafaa El-Sadr Dr. Mathilde Krim* 1999 Dr. Harold Varmus Irene Diamond* Spencer Cox* 2000 Tom Viola, BC/EFA Dr. Anthony S. Fauci Lynda M. Dee, Esq. 2001 Gregg Gonsalves Michael Cunningham Dr. Art Ammann*…
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.
This report marks the midway point of the 1/4/6x24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.
March 2024 Media coverage: Scientists say they can cut HIV out of cells - Michelle Roberts, BBC, March 20, 2024 HIV cure breakthrough as virus eliminated from cells in laboratory - Nina Massey, The Independent, March 20, 2024 Hopes of…
Save the Date: Thursday, October 17, 2024, when our Research in Action Awards return this fall! Once again we'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV).